TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Share Price Singapore S.E.
Equities
T14
CNE100000924
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2 USD | +1.52% |
|
+0.50% | -3.38% |
| Sales 2024 * | 9.05B 1.25B 100B | Sales 2025 * | 9.96B 1.37B 110B | Capitalization | 22.49B 3.1B 249B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.17B 162M 12.96B | Net income 2025 * | 1.4B 193M 15.46B | EV / Sales 2024 * | 2.48 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.26 x |
| P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
18.9
x | Employees | 4,619 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 31.08% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.52% | ||
| 1 week | +0.50% | ||
| Current month | -0.50% | ||
| 1 month | +2.56% | ||
| 3 months | +10.50% | ||
| 6 months | +8.11% | ||
| Current year | -3.38% |
1 week
1.95
2.02
1 month
1.952.05
Current year
1.662.11
1 year
1.662.44
3 years
0.902.44
5 years
0.512.44
10 years
0.512.44
| Managers | Title | Age | Since |
|---|---|---|---|
Lei Wang
CEO | Chief Executive Officer | 53 | 21/08/22 |
Hong Zhou
CTO | Chief Tech/Sci/R&D Officer | 54 | 30/11/12 |
| 42 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ping Zhang
BRD | Director/Board Member | 55 | 29/09/19 |
Yoke Pheng Liew
BRD | Director/Board Member | 68 | 04/06/20 |
Hong Zhou
CTO | Chief Tech/Sci/R&D Officer | 54 | 30/11/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2 | +1.52% | 400,900 |
| 25/04/24 | 1.97 | -1.01% | 322,000 |
| 24/04/24 | 1.99 | 0.00% | 198,600 |
| 23/04/24 | 1.99 | +0.51% | 161,800 |
| 22/04/24 | 1.98 | -0.50% | 104,400 |
Delayed Quote Singapore S.E., April 26, 2024 at 09:59 am
More quotes
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, formerly Tianjin Zhongxin Pharmaceutical Group Co Ltd, is a China-based company mainly engaged in the production, operation and scientific research of green traditional Chinese medicine. The Company's businesses cover the whole industry chain of traditional Chinese medicine, including the cultivation of Chinese medicinal materials, trade of Chinese medicinal materials, research and development (R&D), production and sales of Chinese patent medicines, production and sales of Chinese herbal decoction pieces, pharmaceutical commercial logistics, pharmaceutical retailing, chemical raw materials and preparations, biomedicine and many other fields. The Company's products include cardiovascular and cerebrovascular medicines, respiratory medicines, spleen and stomach medicines, cold medicines, oncology medicines, gynecological medicines, pediatric medicines and other other product groups.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
34.37
CNY
Average target price
45.8
CNY
Spread / Average Target
+33.26%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| +0.09% | 1.65B | |
| -7.89% | 1.68B | |
| -12.97% | 1.53B | |
| +33.40% | 1.38B | |
| +34.29% | 1.3B |
- Stock Market
- Equities
- 600329 Stock
- T14 Stock
